However, despite priming B-ALL cells for apoptosis, trametinib only modestly affected their viability, suggesting that BIM dephosphorylation alone was insufficient to overcome pro-survival signals. The gene discussed is BCL2L11; the disease is acute lymphoblastic leukemia.